Anthracycline cardiotoxicity in survivors of childhood cancer: Clinical course, protection, and treatment

Progress in Pediatric Cardiology

Volumn 36, Issue 1-2, 2014, Pages 11-18

  Bansal, Neha ^a   Franco, Vivian I ^a   Lipshultz, Steven E ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anthracyclines; Cardiac late effects; Cardiotoxicity; Childhood cancer; Childhood cancer survivors; Dexrazoxane

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; AMIFOSTINE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTHRACYCLINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; GROWTH HORMONE; RAZOXANE; TROPONIN I; TROPONIN T;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER SURVIVOR; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR PARAMETERS; CHILD HEALTH CARE; CHILDHOOD CANCER; CONGESTIVE CARDIOMYOPATHY; CONTINUOUS INFUSION; DIET THERAPY; DISEASE ASSOCIATION; DNA DAMAGE; DRUG EFFICACY; DRUG MONITORING; EVENT FREE SURVIVAL; EVIDENCE BASED MEDICINE; EXERCISE; FAT MASS; GENETIC PREDISPOSITION; HEART INJURY; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FRACTIONAL SHORTENING; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE MASS; HEART MUSCLE CONTRACTILITY; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HEMOCHROMATOSIS; HIGH RISK PATIENT; HIGH RISK POPULATION; HORMONE SUBSTITUTION; HUMAN; LIFESTYLE MODIFICATION; LIPID PEROXIDATION; MULTICENTER STUDY (TOPIC); OBESITY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SCINTIANGIOGRAPHY; TREATMENT OUTCOME; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

EID: 84925943320     PISSN: 10589813     EISSN: 15581519     Source Type: Journal    
DOI: 10.1016/j.ppedcard.2014.09.012     Document Type: Review

References (110)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
2. Oeffinger K.C., Mertens A.C., Sklar C.A., et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006, 355:1572-1582.
3. Darzy K.H., Shalet S.M. Hypopituitarism following radiotherapy revisited. Endocr Dev 2009, 15:1-24.
4. Lipshultz S.E., Colan S.D. Cardiovascular trials in long-term survivors of childhood cancer. J Clin Oncol 2004, 22:769-773.
5. Landy D.C., Miller T.L., Lipsitz S.R., et al. Cranial irradiation as an additional risk factor for anthracycline cardiotoxicity in childhood cancer survivors: an analysis from the cardiac risk factors in childhood cancer survivors study. Pediatr Cardiol 2013, 34:826-834.
6. Goorin A.M., Chauvenet A.R., Perez-Atayde A.R., Cruz J., McKone R., Lipshultz S.E. Initial congestive heart failure, six to ten years after doxorubicin chemotherapy for childhood cancer. J Pediatr 1990, 116:144-147.
7. Lipshultz S.E., Alvarez J.A., Scully R.E. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 2008, 94:525-533.
8. Giantris A., Abdurrahman L., Hinkle A., Asselin B., Lipshultz S.E. Anthracycline-induced cardiotoxicity in children and young adults. Crit Rev Oncol Hematol 1998, 27:53-68.
9. Barry E., Alvarez J.A., Scully R.E., Miller T.L., Lipshultz S.E. Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin Pharmacother 2007, 8:1039-1058.
10. Krischer J.P., Epstein S., Cuthbertson D.D., Goorin A.M., Epstein M.L., Lipshultz S.E. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol 1997, 15:1544-1552.
11. Grenier M.A., Lipshultz S.E. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol 1998, 25:72-85.
12. Simbre V.C., Duffy S.A., Dadlani G.H., Miller T.L., Lipshultz S.E. Cardiotoxicity of cancer chemotherapy: implications for children. Paediatr Drugs 2005, 7:187-202.
13. Adams M.J., Lipshultz S.E. Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention. Pediatr Blood Cancer 2005, 44:600-606.
14. Trachtenberg B.H., Landy D.C., Franco V.I., et al. Anthracycline-associated cardiotoxicity in survivors of childhood cancer. Pediatr Cardiol 2011, 32:342-353.
15. Bristow M.R., Mason J.W., Billingham M.E., Daniels J.R. Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann Intern Med 1978, 88:168-175.
16. Lipshultz S.E., Adams M.J., Colan S.D., et al. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation 2013, 128:1927-1995.
17. Lipshultz S.E., Scully R.E., Stevenson K.E., et al. Hearts too small for body size after doxorubicin for childhood ALL: Grinch syndrome. J Clin Oncol 2014, 32:10021. [abstract].
18. Lipshultz S.E., Lipsitz S.R., Mone S.M., et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995, 332:1738-1743.
19. Lipshultz S.E., Colan S.D., Gelber R.D., Perez-Atayde A.R., Sallan S.E., Sanders S.P. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991, 324:808-815.
20. Lipshultz S.E., Lipsitz S.R., Sallan S.E., et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 2005, 23:2629-2636.
21. Kremer L.C., van Dalen E.C., Offringa M., Ottenkamp J., Voute P.A. Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol 2001, 19:191-196.
22. Legha S.S., Benjamin R.S., Mackay B., et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982, 96:133-139.
23. Lipshultz S.E., Miller T.L., Lipsitz S.R., et al. Continuous versus bolus infusion of doxorubicin in children with ALL: long-term cardiac outcomes. Pediatrics 2012, 130:1003-1011.
24. Levitt G.A., Dorup I., Sorensen K., Sullivan I. Does anthracycline administration by infusion in children affect late cardiotoxicity?. Br J Haematol 2004, 124:463-468.
25. Gupta M., Steinherz P.G., Cheung N.K., Steinherz L. Late cardiotoxicity after bolus versus infusion anthracycline therapy for childhood cancers. Med Pediatr Oncol 2003, 40:343-347.
26. Lipshultz S.E., Giantris A.L., Lipsitz S.R., et al. Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol. J Clin Oncol 2002, 20:1677-1682.
27. Tukenova M., Guibout C., Oberlin O., et al. Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J Clin Oncol 2010, 28(8):1308-1315.
28. Armstrong G.T., Oeffinger K.C., Chen Y., et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol 2013, 31:3673-3680.
29. Rodvold K.A., Rushing D.A., Tewksbury D.A. Doxorubicin clearance in the obese. J Clin Oncol 1988, 6:1321-1327.
30. Zhang J., Knapton A., Lipshultz S.E., Cochran T.R., Hiraragi H., Herman E.H. Sex-related differences in mast cell activity and doxorubicin toxicity: a study in spontaneously hypertensive rats. Toxicol Pathol 2014, 42:361-375.
31. Mulrooney D.A., Yeazel M.W., Kawashima T., et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 2009, 339:b4606.
32. Ness K.K., Leisenring W.M., Huang S., et al. Predictors of inactive lifestyle among adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Cancer 2009, 115:1984-1994.
33. Miller T.L., Lipsitz S.R., Lopez-Mitnik G., et al. Characteristics and determinants of adiposity in pediatric cancer survivors. Cancer Epidemiol Biomarkers Prev 2010, 19:2013-2022.
34. Landy D.C., Miller T.L., Lopez-Mitnik G., et al. Aggregating traditional cardiovascular disease risk factors to assess the cardiometabolic health of childhood cancer survivors: an analysis from the Cardiac Risk Factors in Childhood Cancer Survivors Study. Am Heart J 2012, 163:295-301.
35. Miller A.M., Lopez-Mitnik G., Somarriba G., et al. Exercise capacity in long-term survivors of pediatric cancer: an analysis from the Cardiac Risk Factors in Childhood Cancer Survivors Study. Pediatr Blood Cancer 2013, 60:663-668.
36. Meacham L.R., Chow E.J., Ness K.K., et al. Cardiovascular risk factors in adult survivors of pediatric cancer-a report from the childhood cancer survivor study. Cancer Epidemiol Biomarkers Prev 2010, 19:170-181.
37. Messiah S.E., Arheart K.L., Lopez-Mitnik G., Lipshultz S.E., Miller T.L. Ethnic group differences in cardiometabolic disease risk factors independent of body mass index among American youth. Obesity (Silver Spring) 2013, 21:424-428.
38. Razzouk B.I., Rose S.R., Hongeng S., et al. Obesity in survivors of childhood acute lymphoblastic leukemia and lymphoma. J Clin Oncol 2007, 25:1183-1189.
39. Landy D.C., Lipsitz S.R., Kurtz J.M., et al. Dietary quality, caloric intake, and adiposity of childhood cancer survivors and their siblings: an analysis from the cardiac risk factors in childhood cancer survivors study. Nutr Cancer 2013, 65:547-555.
40. Link G., Tirosh R., Pinson A., Hershko C. Role of iron in the potentiation of anthracycline cardiotoxicity: identification of heart cell mitochondria as a major site of iron-anthracycline interaction. J Lab Clin Med 1996, 127:272-278.
41. Lipshultz S.E., Lipsitz S.R., Kutok J.L., et al. Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia. Cancer 2013, 119:3555-3562.
42. Blanco J.G., Leisenring W.M., Gonzalez-Covarrubias V.M., et al. Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer 2008, 112:2789-2795.
43. Blanco J.G., Sun C.L., Landier W., et al. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes-a report from the Children's Oncology Group. J Clin Oncol 2012, 30:1415-1421.
44. Cheitlin M.D., Armstrong W.F., Aurigemma G.P., et al. ACC/AHA/ASE 2003 Guideline Update for the Clinical Application of Echocardiography: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). J Am Soc Echocardiogr 2003, 16:1091-1110.
45. Lipshultz S.E., Sanders S.P., Goorin A.M., Krischer J.P., Sallan S.E., Colan S.D. Monitoring for anthracycline cardiotoxicity. Pediatrics 1994, 93:433-437.
46. Altena R., Perik P.J., van Veldhuisen D.J., de Vries E.G., Gietema J.A. Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol 2009, 10:391-399.
47. Jurcut R., Wildiers H., Ganame J., D'Hooge J., Paridaens R., Voigt J.U. Detection and monitoring of cardiotoxicity-what does modern cardiology offer?. Support Care Cancer 2008, 16:437-445.
48. Bu'Lock F.A., Mott M.G., Oakhill A., Martin R.P. Left ventricular diastolic filling patterns associated with progressive anthracycline-induced myocardial damage: a prospective study. Pediatr Cardiol 1999, 20:252-263.
49. Geyer H., Caracciolo G., Abe H., et al. Assessment of myocardial mechanics using speckle tracking echocardiography: fundamentals and clinical applications. J Am Soc Echocardiogr 2010, 23:351-369. [quiz 453-5].
50. Cooper L.T., Baughman K.L., Feldman A.M., et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. Eur Heart J 2007, 28:3076-3093.
51. Lipshultz S.E., Rifai N., Sallan S.E., et al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation 1997, 96:2641-2648.
52. Cardinale D., Sandri M.T., Colombo A., et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004, 109:2749-2754.
53. Cardinale D., Sandri M.T., Martinoni A., et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 2000, 36:517-522.
54. Herman E.H., Zhang J., Lipshultz S.E., et al. Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 1999, 17:2237-2243.
55. Lipshultz S.E., Rifai N., Dalton V.M., et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 2004, 351:145-153.
56. Dolci A., Dominici R., Cardinale D., Sandri M.T., Panteghini M. Biochemical markers for prediction of chemotherapy-induced cardiotoxicity: systematic review of the literature and recommendations for use. Am J Clin Pathol 2008, 130:688-695.
57. Martinez-Rumayor A., Richards A.M., Burnett J.C., Januzzi J.L. Biology of the natriuretic peptides. Am J Cardiol 2008, 101:3-8.
58. Wang T.J., Larson M.G., Levy D., et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004, 350:655-663.
59. Kragelund C., Gronning B., Kober L., Hildebrandt P., Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 2005, 352:666-675.
60. Grewal J., McKelvie R.S., Persson H., et al. Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. Am J Cardiol 2008, 102:733-737.
61. Ratnasamy C., Kinnamon D.D., Lipshultz S.E., Rusconi P. Associations between neurohormonal and inflammatory activation and heart failure in children. Am Heart J 2008, 155:527-533.
62. Trachtenberg B.H., Hare J.M. Biomarkers of oxidative stress in heart failure. Heart Fail Clin 2009, 5:561-577.
63. Minotti G., Menna P., Salvatorelli E., Cairo G., Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004, 56:185-229.
64. Schorin M.A., Blattner S., Gelber R.D., et al. Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01. J Clin Oncol 1994, 12:40-47.
65. Nysom K., Holm K., Lipsitz S.R., et al. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. J Clin Oncol 1998, 16:545-550.
66. Lipshultz S.E., Scully R.E., Lipsitz S.R., et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol 2010, 11:950-961.
67. Wouters K.A., Kremer L.C., Miller T.L., Herman E.H., Lipshultz S.E. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol 2005, 131:561-578.
68. Fulbright J.M., Huh W., Anderson P., Chandra J. Can anthracycline therapy for pediatric malignancies be less cardiotoxic?. Curr Oncol Rep 2010, 12:411-419.
69. Gabizon A.A., Lyass O., Berry G.J., Wildgust M. Cardiac safety of pegylated liposomal doxorubicin (Doxil/Caelyx) demonstrated by endomyocardial biopsy in patients with advanced malignancies. Cancer Investig 2004, 22:663-669.
70. 2. Ann Oncol 2000, 11:1029-1033.
71. van Dalen E.C., Michiels E.M., Caron H.N., Kremer L.C. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev 2010, CD005006.
72. Marina N.M., Cochrane D., Harney E., et al. Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study. Clin Cancer Res 2002, 8:413-418.
73. Greenlee H., Hershman D.L., Jacobson J.S. Use of antioxidant supplements during breast cancer treatment: a comprehensive review. Breast Cancer Res Treat 2009, 115:437-452.
74. Unverferth D.V., Jagadeesh J.M., Unverferth B.J., Magorien R.D., Leier C.V., Balcerzak S.P. Attempt to prevent doxorubicin-induced acute human myocardial morphologic damage with acetylcysteine. J Natl Cancer Inst 1983, 71:917-920.
75. Ladas E.J., Jacobson J.S., Kennedy D.D., Teel K., Fleischauer A., Kelly K.M. Antioxidants and cancer therapy: a systematic review. J Clin Oncol 2004, 22:517-528.
76. Lyu Y.L., Kerrigan J.E., Lin C.P., et al. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res 2007, 67:8839-8846.
77. Tebbi C.K., London W.B., Friedman D., et al. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol 2007, 25:493-500.
78. Lipshultz S.E., Lipsitz S.R., Orav E.J. Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkin's disease: a claim without compelling evidence. J Clin Oncol 2007, 25:3179. [author reply 80].
79. Hellmann K. Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkin's disease: a claim without evidence. J Clin Oncol 2007, 25:4689-4690. author reply 90-1.
80. van Dalen E.C., Caron H.N., Dickinson H.O., Kremer L.C. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2005, CD003917.
81. Barry E.V., Vrooman L.M., Dahlberg S.E., et al. Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. J Clin Oncol 2008, 26:1106-1111.
82. Asselin B.L., Devidas M., Zhou T., Camitta B.M., Lipshultz S.E. Cardioprotection and safety of dexrazoxane (DRZ) in children treated for newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) or advanced stage lymphoblastic leukemia (T-LL). J Clin Oncol 2012, 30(Suppl):9504. Children's Oncology Group ALL Committee, (abstr).
83. Ebb D., Meyers P., Grier H., et al. Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group. J Clin Oncol 2012, 30:2545-2551.
84. Wexler L.H., Andrich M.P., Venzon D., Berg S.L., Weaver-McClure L., Chen C.C., Dilsizian V., Avila N., Jarosinski P., Balis F.M., Poplack D.G., Horowitz M.E. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol Feb. 1996, 14(2):362-372.
85. Thompson P.A., Rosner G.L., Matthay K.K., et al. Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study. Cancer Chemother Pharmacol 2009, 64:243-251.
86. Calabro-Jones P.M., Aguilera J.A., Ward J.F., Smoluk G.D., Fahey R.C. Uptake of WR-2721 derivatives by cells in culture: identification of the transported form of the drug. Cancer Res 1988, 48:3634-3640.
87. Dragojevic-Simic V.M., Dobric S.L., Bokonjic D.R., et al. Amifostine protection against doxorubicin cardiotoxicity in rats. Anticancer Drugs 2004, 15:169-178.
88. Herman E.H., Zhang J., Chadwick D.P., Ferrans V.J. Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats. Cancer Chemother Pharmacol 2000, 45:329-334.
89. De Flora S., Izzotti A., D'Agostini F., Cesarone C.F. Antioxidant activity and other mechanisms of thiols involved in chemoprevention of mutation and cancer. Am J Med 1991, 91:122S-130S.
90. Myers C., Bonow R., Palmeri S., et al. A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Semin Oncol 1983, 10:53-55.
91. Feuerstein G.Z., Ruffolo R.R. Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. Eur Heart J 1995, 16(Suppl. F):38-42.
92. Matsui H., Morishima I., Numaguchi Y., Toki Y., Okumura K., Hayakawa T. Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats. Life Sci 1999, 65:1265-1274.
93. Spallarossa P., Garibaldi S., Altieri P., et al. Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J Mol Cell Cardiol 2004, 37:837-846.
94. Silber J.H., Cnaan A., Clark B.J., et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol 2004, 22:820-828.
95. Lipshultz S.E., Lipsitz S.R., Sallan S.E., et al. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol 2002, 20:4517-4522.
96. Cardinale D., Colombo A., Lamantia G., et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 2010, 55:213-220.
97. Bruns L.A., Chrisant M.K., Lamour J.M., et al. Carvedilol as therapy in pediatric heart failure: an initial multicenter experience. J Pediatr 2001, 138:505-511.
98. Rusconi P., Gomez-Marin O., Rossique-Gonzalez M., et al. Carvedilol in children with cardiomyopathy: 3-year experience at a single institution. J Heart Lung Transplant 2004, 23:832-838.
99. Williams R.V., Tani L.Y., Shaddy R.E. Intermediate effects of treatment with metoprolol or carvedilol in children with left ventricular systolic dysfunction. J Heart Lung Transplant 2002, 21:906-909.
100. Bristow M.R. Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol 1997, 80:26L-40L.
101. Shaddy R.E., Tani L.Y., Gidding S.S., et al. Beta-blocker treatment of dilated cardiomyopathy with congestive heart failure in children: a multi-institutional experience. J Heart Lung Transplant 1999, 18:269-274.
102. Shaddy R.E., Olsen S.L., Bristow M.R., et al. Efficacy and safety of metoprolol in the treatment of doxorubicin-induced cardiomyopathy in pediatric patients. Am Heart J 1995, 129:197-199.
103. Tallaj J.A., Franco V., Rayburn B.K., et al. Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure. J Heart Lung Transplant 2005, 24:2196-2201.
104. Lipshultz S.E., Vlach S.A., Lipsitz S.R., Sallan S.E., Schwartz M.L., Colan S.D. Cardiac changes associated with growth hormone therapy among children treated with anthracyclines. Pediatrics 2005, 115:1613-1622.
105. Zerra P., Cochran T.R., Franco V.I., Lipshultz S.E. An expert opinion on pharmacologic approaches to reducing the cardiotoxicity of childhood acute lymphoblastic leukemia therapies. Expert Opin Pharmacother 2013, 14:1497-1513.
106. Adams M.J., Lipsitz S.R., Colan S.D., et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol 2004, 22:3139-3148.
107. Miller A.M., Lopez-Mitnik G., Somarriba G., et al. Exercise capacity in long-term survivors of pediatric cancer: an analysis from the Cardiac Risk Factors in Childhood Cancer Survivors Study. Pediatr Blood Cancer 2013, 60:663-668.
108. Lipshultz S.E., Landy D.C., Lopez-Mitnik G., et al. Cardiovascular status of childhood cancer survivors exposed and unexposed to cardiotoxic therapy. J Clin Oncol 2012, 30:1050-1057.
109. Franco V.I., Henkel J.M., Miller T.L., Lipshultz S.E. Cardiovascular effects in childhood cancer survivors treated with anthracyclines. Cardiol Res Pract 2011, 134679.
110. Lipshultz S.E. Ventricular dysfunction clinical research in infants, children and adolescents. Prog Pediatr Cardiol 2000, 12:1-28.